AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 141 min read$LGND

Haas Jason sold $2.1M of LGND

Haas Jason sold 7,138 shares of LIGAND PHARMACEUTICALS INC (LGND) at $292.81 ($2.09M total) on 2026-08-12.

Original reporting
SEC EDGAR · Haas Jason
Published Aug 14, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 11:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LGND
Neutral
medium confidence
Mentioned
$LGND
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LGNDNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this filing alone does not change Ligand’s fundamentals or near-term expectations.

02

Market read

A director open-market sale of about $2.09M is disclosed, which can slightly pressure sentiment but lacks fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the filing does not disclose intent, diversification needs, or whether other insiders are selling/buying concurrently.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-14, transaction dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals, reported via SEC EDGAR.

Company-level read

Ticker impact

$LGNDNeutralMedium confidence
Context

SEC Form 4 shows director Jason Haas sold 7,138 shares of Ligand Pharmaceuticals at $292.8078 on 2026-08-12.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The transaction is a director sale with no 10b5-1 plan stated and no accompanying company news, so it is typically viewed as low-signal unless part of a broader pattern.

Market effects

Sector

Minimal; this is company-specific insider activity with no disclosed sector-wide regulatory or clinical development.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity or tax-related, especially without any stated link to company performance.

Key entities

  • issuer
    LGND

    Ligand Pharmaceuticals Inc., the company whose director insider sale is disclosed.

  • insider
    Haas Jason

    Director of Ligand Pharmaceuticals who sold shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LGND insider trading history →

Related articles

SEP 27
$LGNDMed

Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones

Ligand Pharmaceuticals (LGND) announced a $47M financing deal with AvenCell Therapeutics, including $6M for Series C funding and $41M for drug development, tied to milestones. Ligand aims for mid-single-digit to low-double-digit royalties on AvenCell's sales. The company's royalty revenue grew 32% YoY to $48M in Q2, with a target of $225M-$250M for 2026. Ligand has $1.36B in cash and $700M for further investments.

insidermonkey.com2 min
SEP 24
$LGNDMed

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., September 24, 2026 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a f

SEC EDGAR 8-K1 min
SEP 4
$LGNDHighAI 8/10

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.

insidermonkey.com3 min
AUG 13
$LGNDHighAI 9/10

Ligand (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.

fool.com6 min
AUG 8
$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min